Santen Pharmaceutical Co., Ltd. and Mitsubishi Tanabe Pharma Corporation concluded a joint sales promotion contract concerning Alesion® Ophthalmic Solution 0.05% (JAN: Epinastine Hydrochloride; hereinafter, "Alesion"), which is an anti-allergenic ophthalmic solution currently manufactured and marketed by Santen, and Alesion LX, for which Santen has recently obtained approval. Based on this contract, Santen will manufacture and distribute the products, while both companies will conduct promotional activities to medical institutions starting October 1, 2019. Santen will be in charge of medical institutions of ophthalmology, and Mitsubishi Tanabe Pharma will be in charge of medical institutions other than ophthalmology.